The availability of three iron chelators improved the scenario of chelation therapy for
transfusion-dependent thalassemia (TDT) patients, allowing tailoring of drugs according to …

Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …

For the past 2–6 years, two groups of thalassemia patients, one of 16 patients on
deferoxamine (DFO) monotherapy (35–80 mg/kg, 2–5 days/week) and the other group …

Objectives: The benefits of combined chelation therapy with daily deferiprone (DFP) and
subcutaneous desferrioxamine (DFO) have been widely reported in literature. We …

Transfusional hemosiderosis is a frequent complication in patients with transfusion
dependent chronic diseases such as thalassemias and severe type of sickle cell diseases …

BACKGROUND AND OBJECTIVES: Iron accumulation is an inevitable consequence of
chronic blood transfusions and results in serious complications in the absence of chelation …

Transfusional iron overload is a major target in the care of patients with transfusion-
dependent thalassemia (TDT) and other refractory anemias. Iron accumulates in the liver …

Abstract Background and Objectives The aim of this prospective, randomized, 1-year study
was to compare the efficacy and safety of oral deferiprone (DFP) with those of combinations …

Iron overload is one of the major causes of morbidity in patients with thalassemia major.
Deferiprone (DFP), an orally active iron chelator, emerged from an extensive search for new …

Deferiprone has been suggested as an effective oral chelation therapy for thalassemia
major. To assess its clinical efficacy, we compared deferiprone with deferoxamine in a large …